

## **Sanofi Pasteur information on the divestment project of its anti-venom immunoglobulin range - January 2018**

“Sanofi Pasteur confirms that it has signed a definitive agreement to divest its anti-venom immunoglobulin range to MicroPharm, a UK-based company with recognized expertise in the manufacturing of immunoglobulins. MicroPharm was selected on the basis that it best meets the key selection criterion set down by Sanofi Pasteur, namely the ability to ensure the short, medium, and long-term availability of quality immunoglobulins to meet patients’ needs. The products concerned by the divestment project include BOTHROFAV®, FAV-AFRIQUE®, FAVIREPT®, SCORPIFAV®, and VIPERFAV®.”